Mersana Therapeutics Aktie (A2DTR7

Aktuelle Nachrichten zu Mersana Therapeutics

Weitere Nachrichten

Unsere neuesten Artikel zu Mersana Therapeutics

Zusammenarbeit der Pharmakonzerne Merck und Mersana – Merck sichert sich Exklusivlizenz

Kooperation der Pharmakonzerne bei der Entwicklung zu immunstimulatorischer Antikörperwirkstoff Konjugate.

Das berichten andere über Mersana Therapeutics

Day One Bio (DAWN) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DATETuesday, Feb. 24, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Dr. Jeremy BenderChief Commercial Officer — Lauren MerendinoChief...

Day One Completes Acquisition of Mersana Therapeutics

Day One Bio today announced the successful close of its acquisition of Mersana Therapeutics, Inc.

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ: MRSN), please note that there was a transcription error in the last cell of...

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing...